Immunogen | IMGN - Koszty Sprzedaży I Administracji



Koszty Sprzedaży I Administracji Zmiana Data
AbbVie USD 3.58B 316M 2026-03
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Amgen USD 1.58B 354M 2026-03
Astellas Pharma JPY 234.7B 12.92B 2026-03
AstraZeneca USD 5.06B 455M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Eli Lilly USD 2.93B 198M 2026-03
Emergent BioSolutions USD 182.8M 82.3M 2023-06
Exelixis USD 139.6M 16.58M 2026-03
Halozyme Therapeutics USD 46.29M 18.35M 2026-03
Heron Therapeutics USD 23.74M 605K 2025-12
Intrexon USD 10.31M 41K 2024-06
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
MacroGenics USD 7.94M 1.96M 2025-12
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Novartis USD 3.44B 132M 2025-12
Pfizer USD 2.92B 1.16B 2026-03
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Sanofi EUR 2.75B 455M 2025-12